AZENTA INC (AZTA) Stock Fundamental Analysis
USA - NASDAQ:AZTA - US1143401024 - Common Stock
30.6 USD
+0.08 (+0.26%)
30.6 USD
0 (0%)
Taking everything into account, AZTA scores 4 out of 10 in our fundamental rating. AZTA was compared to 56 industry peers in the Life Sciences Tools & Services industry. AZTA has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, AZTA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AZTA was profitable.
AZTA had a positive operating cash flow in the past year.
In multiple years AZTA reported negative net income over the last 5 years.
Of the past 5 years AZTA 4 years had a positive operating cash flow.
1.2 Ratios
AZTA has a Return On Assets (-5.53%) which is in line with its industry peers.
AZTA's Return On Equity of -6.67% is in line compared to the rest of the industry. AZTA outperforms 53.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.53% | ||
| ROE | -6.67% | ||
| ROIC | N/A |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AZTA's Gross Margin of 44.92% is in line compared to the rest of the industry. AZTA outperforms 44.64% of its industry peers.
In the last couple of years the Gross Margin of AZTA has remained more or less at the same level.
AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AZTA has less shares outstanding
The number of shares outstanding for AZTA has been reduced compared to 5 years ago.
Compared to 1 year ago, AZTA has a worse debt to assets ratio.
2.2 Solvency
AZTA has an Altman-Z score of 3.88. This indicates that AZTA is financially healthy and has little risk of bankruptcy at the moment.
AZTA has a Altman-Z score of 3.88. This is in the better half of the industry: AZTA outperforms 75.00% of its industry peers.
There is no outstanding debt for AZTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.88 |
ROIC/WACCN/A
WACC10.46%
2.3 Liquidity
AZTA has a Current Ratio of 2.76. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
AZTA has a Current ratio of 2.76. This is comparable to the rest of the industry: AZTA outperforms 50.00% of its industry peers.
AZTA has a Quick Ratio of 2.44. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.44, AZTA is in line with its industry, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.44 |
3. Growth
3.1 Past
AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.89%, which is quite impressive.
The earnings per share for AZTA have been decreasing by -12.07% on average. This is quite bad
Looking at the last year, AZTA shows a decrease in Revenue. The Revenue has decreased by -8.15% in the last year.
AZTA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.41% yearly.
EPS 1Y (TTM)38.89%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%18.75%
Revenue 1Y (TTM)-8.15%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-16.7%
3.2 Future
Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.43% on average per year.
Based on estimates for the next years, AZTA will show a small growth in Revenue. The Revenue will grow by 2.23% on average per year.
EPS Next Y23.82%
EPS Next 2Y38.65%
EPS Next 3Y35.16%
EPS Next 5Y29.43%
Revenue Next Year-9.64%
Revenue Next 2Y-3.05%
Revenue Next 3Y-0.57%
Revenue Next 5Y2.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AZTA is valuated quite expensively with a Price/Earnings ratio of 61.20.
The rest of the industry has a similar Price/Earnings ratio as AZTA.
The average S&P500 Price/Earnings ratio is at 27.50. AZTA is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 38.82, AZTA can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, AZTA is valued a bit cheaper than the industry average as 60.71% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.99, AZTA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.2 | ||
| Fwd PE | 38.82 |
4.2 Price Multiples
AZTA's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AZTA is cheaper than 62.50% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AZTA indicates a somewhat cheap valuation: AZTA is cheaper than 73.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.71 | ||
| EV/EBITDA | 28.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZTA does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as AZTA's earnings are expected to grow with 35.16% in the coming years.
PEG (NY)2.57
PEG (5Y)N/A
EPS Next 2Y38.65%
EPS Next 3Y35.16%
5. Dividend
5.1 Amount
AZTA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.6
+0.08 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners116.57%
Inst Owner ChangeN/A
Ins Owners0.63%
Ins Owner Change1.52%
Market Cap1.40B
Analysts71.43
Price Target32.06 (4.77%)
Short Float %7.79%
Short Ratio5.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.12%
Min EPS beat(2)-29.97%
Max EPS beat(2)36.22%
EPS beat(4)3
Avg EPS beat(4)28.83%
Min EPS beat(4)-29.97%
Max EPS beat(4)71.81%
EPS beat(8)7
Avg EPS beat(8)146.76%
EPS beat(12)10
Avg EPS beat(12)157.49%
EPS beat(16)13
Avg EPS beat(16)123.07%
Revenue beat(2)0
Avg Revenue beat(2)-2.89%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)-0.22%
Revenue beat(4)0
Avg Revenue beat(4)-2.14%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)-0.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.03%
Revenue beat(16)7
Avg Revenue beat(16)-4.7%
PT rev (1m)0%
PT rev (3m)-18.01%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)4.92%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)12.94%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)0.4%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.2 | ||
| Fwd PE | 38.82 | ||
| P/S | 2.32 | ||
| P/FCF | 30.71 | ||
| P/OCF | 16.75 | ||
| P/B | 0.84 | ||
| P/tB | 1.63 | ||
| EV/EBITDA | 28.53 |
EPS(TTM)0.5
EY1.63%
EPS(NY)0.79
Fwd EY2.58%
FCF(TTM)1
FCFY3.26%
OCF(TTM)1.83
OCFY5.97%
SpS13.2
BVpS36.51
TBVpS18.8
PEG (NY)2.57
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.53% | ||
| ROE | -6.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.92% | ||
| FCFM | 7.55% |
ROA(3y)16.36%
ROA(5y)11.87%
ROE(3y)17.86%
ROE(5y)13.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.44%
GM growth 5Y-0.19%
F-Score7
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 53.88% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 231.56% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.44 | ||
| Altman-Z | 3.88 |
F-Score7
WACC10.46%
ROIC/WACCN/A
Cap/Depr(3y)77.14%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.52%
Cap/Sales(5y)9.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.89%
EPS 3Y-45.83%
EPS 5Y-12.07%
EPS Q2Q%18.75%
EPS Next Y23.82%
EPS Next 2Y38.65%
EPS Next 3Y35.16%
EPS Next 5Y29.43%
Revenue 1Y (TTM)-8.15%
Revenue growth 3Y8.51%
Revenue growth 5Y-3.41%
Sales Q2Q%-16.7%
Revenue Next Year-9.64%
Revenue Next 2Y-3.05%
Revenue Next 3Y-0.57%
Revenue Next 5Y2.23%
EBIT growth 1Y55.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1010.56%
EBIT Next 3Y149.86%
EBIT Next 5Y112.74%
FCF growth 1Y182.14%
FCF growth 3Y-48.98%
FCF growth 5Y-28.07%
OCF growth 1Y759.23%
OCF growth 3Y-30.52%
OCF growth 5Y-11.17%